Converting Intravenous Dosing to Subcutaneous Dosing With Recombinant Human Hyaluronidase - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Converting Intravenous Dosing to Subcutaneous Dosing With Recombinant Human Hyaluronidase
The preferred route of administration for an injected therapeutic agent is subcutaneous (SC), but SC injections are generally limited to no more than 1-2 mL in volume, representing a major challenge, especially for large protein biologics.


Pharmaceutical Technology


2. J. Prettyman, "Subcutaneous or Intramuscular? Confronting a Parenteral Administration Dilemma," Medsurg. Nursing, 14 (2), 93–98 (2005).

3. H.C. Ansel, L.V. Allen, and N.G. Popovich, Pharmaceutical Dosage Forms and Drug Delivery Systems (Lippincott Williams & Wilkins, Philadelphia, PA, 8th ed., 2004).

4. A.L. Alcantara et al.,"Radiologic Study of Injection Drug Use Complications," Infect. Dis. Clin. North Am. 16 (3), 713–743 (2002).

5. P.D. Brown and J.R. Ebright, "Skin and Soft Tissue Infections in Injection Drug Users," Curr. Infect. Dis. Rep. 4 (5), 415–419 (2002).

6. S. Satyanarayana and A.D. Mathur, "Atypical Mycobacterial Injection Abscess," J. Indian Med. Assoc. 101 (1), 36–40 (2003).

7. S.C. DeWitt, Fundamental Concepts and Skills for Nursing (WB Saunders Company, Philadelphia, PA, 2001).

8. P.S. Bergeson, S.A. Singer, and A.M. Kaplan, "Intramuscular Injections in Children," Pediatrics 70 (6), 944–948 (1982).

9. A. Supersaxo, W.R. Hein, and H. Steffen, "Effect of Molecular Weight on the Lymphatic Absorption of Water-soluble Compounds Following Subcutaneous Administration," Pharm. Res. 7 (2), 167–179 (1990).

10. Campath (alemtuzumab) Package Insert, Bayer Healthcare Pharmaceuticals, Wayne, NJ, Jan. 2007.

11. M.C. Hochberg et al., "Comparison of the Efficacy of the Tumor Necrosis Factor α-Blocking Agents Adalimumab, Etanercept, and Infliximab When Added to Methotrexate in Patients with Active Rheumatoid Arthritis," Ann. Rheum. Dis. 62 (suppl 2), ii13–ii16 (2003).

12. E. Nemser and D. Azad, "Assessing the Impact of Differential Reimbursement of Medicare Pharmacy Benefits," Biotechnology Healthcare, Aug. 47–51 (2005).

13. T.D. Day, "The Permeability of Extracellular Connective Tissue and the Nature of the Interfibrillary Substance," J. Physiol. 117 (1), 1–8 (1952).

14. A.H. Paes, A. Bakker, and C.J. Soe-Agnie, "Impact of Dosage Frequency on Patient Compliance," Diabetes Care 20 (10), 1512–1517 (1997).

15. G.I Frost, "Recombinant Human Hyaluronidase (rHuPH20): An Enabling Platform for Subcutaneous and Fluid Administration," Expert Opin. Drug. Del. 4 (4), 427–440 (2007).

16. N. Verzijl et al., "Effect of Collagen Turnover on the Accumulation of Advanced Glycation End Products," J. Biol. Chem. 15 (50), 39027–39031 (2000).

17. U.B.G. Laurent, L.B. Dahl, and P.K. Reed, "Catabolism of Hyaluronan in Rabbit Skin Takes Place Locally in Lymph Nodes and Liver," Exp. Physiol. 76 (5), 695–703 (1991).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here